Search Results

You are looking at 91 - 100 of 523 items for :

  • Refine by Access: All content x
Clear All
Free access

Yu-Li Chen, Cheng-Yang Chou, Ming-Cheng Chang, Han-Wei Lin, Ching-Ting Huang, Shu-Feng Hsieh, Chi-An Chen, and Wen-Fang Cheng

findings, disease relapse, and prognosis. The characteristics of disease were defined according to the system of International Federation of Gynecology and Obstetrics (FIGO) (1971) . Stage I and II diseases were considered to be early stage, and stages III

Free access

Elisa Roca, Alfredo Berruti, Silviu Sbiera, Ida Rapa, Ester Oneda, Paola Sperone, Cristina L Ronchi, Laura Ferrari, Salvatore Grisanti, Antonina Germano, Barbara Zaggia, Giorgio Vittorio Scagliotti, Martin Fassnacht, Marco Volante, Massimo Terzolo, and Mauro Papotti

curative approach, most of the radically resected patients are destined to relapse, often with metastases ( Bellantone et al . 1997 , Icard et al . 2001 ). Mitotane is the reference systemic therapy for ACC ( Hahner & Fassnacht 2005 ). On the basis of

Open access

Catherine Zabkiewicz, Jeyna Resaul, Rachel Hargest, Wen Guo Jiang, and Lin Ye

breast cancers ( Cancer Research UK 2017 ). Even for those treated at an early stage, there is still a significant risk of relapse, often several years later. This is particularly true of oestrogen receptor-positive breast cancers, which are at a

Free access

Alison J Butt, Catriona M McNeil, Elizabeth A Musgrove, and Robert L Sutherland

). Furthermore, MYC amplification increased the risk of relapse and death ( Naidu et al. 2002 , Schlotter et al. 2003 , Al-Kuraya et al. 2004 ). However, there are few data evaluating the effect of MYC amplification on response to endocrine therapy in

Free access

Cristina Gurizzan, Manuel Zamparini, Marco Volante, Valeria Tovazzi, Vito Amoroso, Francesca Consoli, Fausto Petrelli, Salvatore Grisanti, Paolo Bossi, and Alfredo Berruti

dose (Gy) Median 60 (range 50–66) Recurrent disease h 29 (24) Site of recurrence  Locoregional 21 (72)  Distant 5 (17)  Locoregional + distant 3 (11) Treatment at locoregional relapse  Surgery 11

Free access

Stephanie Metcalf, Belinda J Petri, Traci Kruer, Benjamin Green, Susan Dougherty, James L Wittliff, Carolyn M Klinge, and Brian F Clem

-approved institutional biorepository ( Wittliff et al. 2008 ) or within the online database KM Plotter ( ( Mihaly et al. 2013 ). Correlation of PSAT1 expression against relapse-free survival (RFS) was performed using a microarray dataset acquired from

Free access

Duane H Hamilton, Mario Roselli, Patrizia Ferroni, Leopoldo Costarelli, Francesco Cavaliere, Mariateresa Taffuri, Claudia Palena, and Fiorella Guadagni

rate of tumor relapse compared with patients with other subtypes of breast cancer ( Carey et al . 2006 , Haffty et al . 2006 , Dent et al . 2007 , O’Brien et al . 2010 ). With the recent use of genome-wide expression analysis, breast cancer has

Free access

Sarah E McClelland

chromosome mis-segregation, which promoted efficient tumour relapse following withdrawal of KRAS dependency ( Sotillo et al. 2010 ). However, it remains challenging to test these principles in controlled human cellular systems directly as this requires the

Free access

Olimpia Alice Manzardo, Miriam Cellini, Rita Indirli, Alessia Dolci, Paolo Colombo, Flaminia Carrone, Elisabetta Lavezzi, Giovanna Mantovani, Gherardo Mazziotti, Maura Arosio, and Andrea Gerardo Antonio Lania

–28,090) Reoperation (%) Second line treatments (%) 29 (6) 10 (2.1) Follow-up Relapses (%) Deaths from thyroid cancer (%) 41 (9.2) 0 (0) Initial ATA risk stratification Low risk (%) Intermediate risk (%) High risk (%) 251 (52.3) 196 (40.8) 33 (6

Free access

Claudio Zamagni, Ralph M Wirtz, Pierandrea De Iaco, Marta Rosati, Elke Veltrup, Federica Rosati, Elisa Capizzi, Nicoletta Cacciari, Carlo Alboni, Alessandra Bernardi, Francesco Massari, Sara Quercia, Antonietta D'Errico Grigioni, Manfred Dietel, Jalid Sehouli, Carsten Denkert, and Andrea Angelo Martoni

year ( Ferlay et al . 2004 ). Unfortunately, most patients (70%) are diagnosed at an advanced stage and the majority of them will relapse, and ultimately die of the disease. Major improvements in ovarian cancer therapy are warranted and the development